DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the BROOKS LAB LIMITED (BROOKS) share price today?

BROOKS LAB LIMITED (BROOKS) is trading at ₹69.46 on the NSE, down 0.47% on the day. Source: DocStoX.

What is the PE ratio of BROOKS LAB LIMITED?

BROOKS LAB LIMITED has a price-to-earnings (PE) ratio of 8.3 in the Healthcare sector.

What is the market capitalisation of BROOKS LAB LIMITED?

BROOKS LAB LIMITED has a market capitalisation of approximately ₹205 crore.

BROOKS LAB LIMITED

BROOKS·NSE·Healthcare

₹69.46▼ -0.33 (-0.47%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

Day₹68.53

₹71.50

52W₹36

₹16426%

Open

₹71.00

High

₹71.50

Low

₹68.53

Prev Close

₹69.79

Volume

11.6K

VWAP

₹70.24

Snapshot

Key fundamentals

Market Cap

₹205 Cr

P/E Ratio

8.33Cheap

P/B Ratio

1.82

EPS

₹8.34

Book Value

₹41.60

ROE

22.30%Strong

ROCE

21.00%Efficient

Dividend Yield

0.00%

Debt / Equity

0.07Low

Face Value

₹10.00

52W High

₹164.02

52W Low

₹36.30

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

None moatHigh uncertainty

Fair value estimate

₹57

▼ 18.4%downside

Trading at ₹69 — 18% above our estimate

BearFair valueBull

₹48₹57₹88

/100

Business quality — Solid

Growth 44Profitability 93Efficiency 33Valuation 98

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Strong returns on equity (22%)
Capital is working hard (ROCE 21%)
Reasonably priced at 8× earnings

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

22% ROE fading to 12% over ~3 yrs, on ₹42 book

₹48

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹88

Analyst target

No analyst coverage

—

Blended fair value₹57

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (22%)
Capital is working hard (ROCE 21%)
Reasonably priced at 8× earnings
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

8.3Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

22.3%Strong

Above 15% is considered healthy for Indian equities

ROCE

21.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.07Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹205 Cr

P/B

1.82

EPS

₹8.34

Div Yield

—

What changed

Recent changes

Foreign investors-0.2% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 8.3×

Growth

Steady

+11% rev CAGR

Profitability

Excellent

22.3% ROE

Financial health

Rock solid

D/E 0.07

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹8.14L Cr

Trades101

VWAP₹70.24

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+10.9%

+2.2%

10Y

+0.7%

Profit

—

10Y

+8.9%

EPS

—

10Y

+6.9%

Profile

Pros

Company is almost debt free.
Company has delivered good profit growth of 26.8% CAGR over last 5 years

Watch-outs

Cons

The company has delivered a poor sales growth of 2.11% over past five years.
Company has a low return on equity of -1.91% over last 3 years.
Contingent liabilities of Rs.75.7 Cr.
Earnings include an other income of Rs.20.0 Cr.
Promoter holding has decreased over last 3 years: -13.8%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 0.17 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

53%

Promoter

Promoters

52.6%0.00

Public

37.0%+0.16

FII / FPI

0.0%-0.17

DII

10.4%0.00

Quarterly trend

Ownership over time

Q1 FY27

Promoter52.62%

DII10.38%

Public37.00%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]